Articles from Reneo Pharmaceuticals, Inc.; OnKure Therapeutics, Inc.
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer
By Reneo Pharmaceuticals, Inc.; OnKure Therapeutics, Inc. · Via GlobeNewswire · October 4, 2024